Ontology highlight
ABSTRACT:
SUBMITTER: Jain P
PROVIDER: S-EPMC3743466 | biostudies-literature | 2013 Jun
REPOSITORIES: biostudies-literature
Jain Preetesh P Kantarjian Hagop H Nazha Aziz A O'Brien Susan S Jabbour Elias E Romo Carlos Guillermo CG Pierce Sherry S Cardenas-Turanzas Marylou M Verstovsek Srdan S Borthakur Gautam G Ravandi Farhad F Quintás-Cardama Alfonso A Cortes Jorge J
Blood 20130425 24
Early responses to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML)-chronic phase (CP) are associated with improved outcome. We analyzed the impact of such a response on outcomes among patients treated with 4 TKI modalities as frontline therapy in CML-CP. A total of 483 patients who received 400 or 800 mg imatinib, nilotinib, or dasatinib were analyzed. The median follow-up was 72 mo. Landmark analysis at 3 mo by molecular response showed that the cumulative proportions of 3-y ...[more]